Application Of Platform Approaches To The Development Of Bispecific Antibodies

By Sam Maurice, Carl Capps, Shaun Lawson, Dan Maltman, Carl Grant, and Rebecca Abram

While monoclonal antibodies (mAbs) readily fit platform approaches to purification and product quality analytics, the variable physicochemical properties of bispecific mAbs (BsAbs) mean that they are prone to fragmentation, formation of homodimers and aggregation. These challenges, coupled with low titer and yield, can ultimately lead to more extensive processes and analytical development when compared to mAbs.

Our mAb purification platform has proven itself to be suitable for the purification of proteins both from client-specific cell lines as well as from Apollo™X. In this scenario, we describe the purification of a BsAb generated outside of our Apollo™X platform and the application of our mAb platform purification approach.